Liver diseases including non-alcoholic fatty liver disease, viral hepatitis, autoimmune hepatitis, and hepatocellular carcinoma represent a growing global health burden with complex pathogenesis and progression pathways. The molecular mechanisms underlying liver disease development remain incompletely characterized, particularly regarding the interplay between genetic predisposition, metabolic dysregulation, inflammatory responses, and structural liver damage. This study aims to comprehensively elucidate the multi-omics landscape of liver diseases using UK Biobank’s extensive multimodal data. We will first identify genomic variants associated with various liver conditions, focusing on pathways involving lipid metabolism, immune regulation, fibrogenesis, and detoxification processes. Second, we will analyze plasma metabolomic and proteomic profiles to characterize circulating biomarkers that reflect hepatic function, injury severity, and disease activity, including metabolites related to bile acid metabolism, lipid species, and inflammatory mediators. Third, we will integrate quantitative imaging features from abdominal MRI, ultrasound, and elastography with molecular data to develop predictive models for disease progression and complication risks. Our integrated approach will bridge molecular mechanisms with clinical manifestations, ultimately aiming to improve early detection accuracy and enable personalized management strategies for patients with various liver conditions.
